The development of a comprehensive immunotherapy based on anti-CCR4 antibody for hematological malignancies

基于抗CCR4抗体的血液恶性肿瘤综合免疫疗法的开发

• 批准号: 22689029
• 负责人: ISHIDA Takashi
• 金额: $ 14.06万
• 依托单位: Nagoya City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (A)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22689029/
• 关键词: CCR4; CCR4 抗体; 制御性 T 細胞; CTL; ATL; NOG マウス; ポテリジオ; 制御性T細胞; HTLV-1; Tax; Mogamulizumab; がん・精巣抗原; KW-0761; NOGマウス

1． Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma (ATL)2． Cancer Testis antigens are potential molecular targets for immunotherapy of ATL.3． Allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL.4． KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile.5． The reduction of Treg cells by mogamulizumab in cancer patients would have bothpotential benefits leading to enhanced antitumor immunity, but also pose risks of autoimmune disease.

1。税是成人T细胞白血病/淋巴瘤（ATL）2的免疫疗法的潜在分子靶标。癌睾丸抗原是ATL免疫疗法的潜在分子靶标。同种异体HSCT不仅具有MAC，而且还具有RIC是一种有效的治疗方法，可导致某些ATL.4患者长期存活。 KW-0761在中继ATL患者中表现出临床意义的抗肿瘤活性，具有可接受的毒性特征。5。癌症患者中摩珠单抗对Treg细胞的减少将具有双重益处，从而增强抗肿瘤免疫（and），但同时也带来了自身免疫性疾病的风险。

项目成果

Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model.

• DOI: 10.1038/bcj.2012.12
• 发表时间: 2012-04
• 期刊: BLOOD CANCER JOURNAL
• 影响因子: 12.8
• 作者: Mori, F.;Ishida, T.;Ito, A.;Sato, F.;Masaki, A.;Takino, H.;Ri, M.;Kusumoto, S.;Komatsu, H.;Ueda, R.;Inagaki, H.;Iida, S.
• 通讯作者: Iida, S.

A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.

补体依赖性细胞毒性增强抗 CD20 抗体在人源化 NOD/Shi-scid、IL-2Rγ(null) 小鼠淋巴瘤模型中介导有效的抗肿瘤活性。

• 发表时间: 2010
• 期刊: Cancer Immunol Immunother.
• 作者: Sato F;Komatsu H;et al
• 通讯作者: et al

Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports

• DOI: 10.1007/s12185-010-0592-y
• 发表时间: 2010-06-01
• 期刊: INTERNATIONAL JOURNAL OF HEMATOLOGY
• 影响因子: 2.1
• 作者: Yoshida, Tatsuya;Kusumoto, Shigeru;Ueda, Ryuzo
• 通讯作者: Ueda, Ryuzo

Immunopathogenesis of lymphoma : Focus on CCR4. 2011 : 102 : 44-50

淋巴瘤的免疫发病机制：关注 CCR4。

• 发表时间: 2011
• 期刊: Cancer Sci
• 影响因子: 5.7
• 作者: Ishida T;Ueda R.(corresponding author)
• 通讯作者: Ueda R.(corresponding author)

Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing.

• DOI: 10.1038/bcj.2012.26
• 发表时间: 2012-07
• 期刊: BLOOD CANCER JOURNAL
• 影响因子: 12.8
• 作者: Ri, M.;Tashiro, E.;Oikawa, D.;Shinjo, S.;Tokuda, M.;Yokouchi, Y.;Narita, T.;Masaki, A.;Ito, A.;Ding, J.;Kusumoto, S.;Ishida, T.;Komatsu, H.;Shiotsu, Y.;Ueda, R.;Iwawaki, T.;Imoto, M.;Iida, S.
• 通讯作者: Iida, S.